Bimekizumab in patients with moderate to severe plaque psoriasis by bodyweight: Pooled results from phase 3 trials

Main Article Content

Andreas Pinter
Bruce Strober
David Rosmarin
Paolo Gisondi
Veerle Vanvoorden
Luke Peterson
Cynthia Madden
Dirk de Cuyper
Richard B Warren


bimekizumab, psoriasis, moderate to severe, phase 3, clinical trial, pooled results, bodyweight, dosing




1. Puig L. J Eur Acad Dermatol 2011;25:1,007–011

2. Warren RB. N Engl J Med 2021;385:130–41

3. Reich K. Lancet 2021;397:487–98

4. Reich K. N Engl J Med 2021;385:142–52

5. Gordon KB. Lancet 2021;397:475–86

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 > >>